These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28152546)

  • 1. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
    Bendell JC; Javle M; Bekaii-Saab TS; Finn RS; Wainberg ZA; Laheru DA; Weekes CD; Tan BR; Khan GN; Zalupski MM; Infante JR; Jones S; Papadopoulos KP; Tolcher AW; Chavira RE; Christy-Bittel JL; Barrett E; Patnaik A
    Br J Cancer; 2017 Feb; 116(5):575-583. PubMed ID: 28152546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
    Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
    J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
    Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
    Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
    Finn RS; Ahn DH; Javle MM; Tan BR; Weekes CD; Bendell JC; Patnaik A; Khan GN; Laheru D; Chavira R; Christy-Bittel J; Barrett E; Sawyer MB; Bekaii-Saab TS
    Invest New Drugs; 2018 Dec; 36(6):1037-1043. PubMed ID: 29785570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
    Banerji U; Camidge DR; Verheul HM; Agarwal R; Sarker D; Kaye SB; Desar IM; Timmer-Bonte JN; Eckhardt SG; Lewis KD; Brown KH; Cantarini MV; Morris C; George SM; Smith PD; van Herpen CM
    Clin Cancer Res; 2010 Mar; 16(5):1613-23. PubMed ID: 20179232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
    Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
    Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
    Guo C; Chénard-Poirier M; Roda D; de Miguel M; Harris SJ; Candilejo IM; Sriskandarajah P; Xu W; Scaranti M; Constantinidou A; King J; Parmar M; Turner AJ; Carreira S; Riisnaes R; Finneran L; Hall E; Ishikawa Y; Nakai K; Tunariu N; Basu B; Kaiser M; Lopez JS; Minchom A; de Bono JS; Banerji U
    Lancet Oncol; 2020 Nov; 21(11):1478-1488. PubMed ID: 33128873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
    Falchook GS; Lewis KD; Infante JR; Gordon MS; Vogelzang NJ; DeMarini DJ; Sun P; Moy C; Szabo SA; Roadcap LT; Peddareddigari VG; Lebowitz PF; Le NT; Burris HA; Messersmith WA; O'Dwyer PJ; Kim KB; Flaherty K; Bendell JC; Gonzalez R; Kurzrock R; Fecher LA
    Lancet Oncol; 2012 Aug; 13(8):782-9. PubMed ID: 22805292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
    Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
    Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
    Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
    Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.
    Lowery MA; Bradley M; Chou JF; Capanu M; Gerst S; Harding JJ; Dika IE; Berger M; Zehir A; Ptashkin R; Wong P; Rasalan-Ho T; Yu KH; Cercek A; Morgono E; Salehi E; Valentino E; Hollywood E; O'Reilly EM; Abou-Alfa GK
    Clin Cancer Res; 2019 Feb; 25(3):937-945. PubMed ID: 30563938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
    Van Cutsem E; Yaeger R; Delord JP; Tabernero J; Siu LL; Ducreux M; Siena S; Elez E; Kasper S; Zander T; Steeghs N; Murphy D; Edwards M; Wainberg ZA
    Oncologist; 2023 Dec; 28(12):e1209-e1218. PubMed ID: 37597246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
    Cohen RB; Aamdal S; Nyakas M; Cavallin M; Green D; Learoyd M; Smith I; Kurzrock R
    Eur J Cancer; 2013 May; 49(7):1521-9. PubMed ID: 23433846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
    Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
    Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
    Jamieson D; Griffin MJ; Sludden J; Drew Y; Cresti N; Swales K; Merriman M; Allen R; Bevan P; Buerkle M; Mala C; Coyle V; Rodgers L; Dean E; Greystoke A; Banerji U; Wilson RH; Evans TR; Anthoney A; Ranson M; Boddy AV; Plummer R
    Eur J Cancer; 2016 Nov; 68():1-10. PubMed ID: 27693888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
    Tolcher AW; Kurzrock R; Valero V; Gonzalez R; Heist RS; Tan AR; Means-Powell J; Werner TL; Becerra C; Wang C; Leonowens C; Kalyana-Sundaram S; Kleha JF; Gauvin J; D'Amelio AM; Ellis C; Ibrahim N; Yan L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):673-683. PubMed ID: 32062691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.